{{Drugbox
| IUPAC_name               = (3''S'',5''R'')-3-amino-5-methyloctanoic acid
| image                    = Imagabalin.svg
| CAS_number               = 610300-07-7
| CAS_supplemental         = <br />610300-00-0 ([[hydrochloride]])
| ATC_prefix               = None
| ATC_suffix               = 
| KEGG = D09627
| C = 9 | H = 19 | N = 1 | O = 2
| molecular_weight         = 173.253 g/mol
| synonyms                 = PD-0332334; PD-332,334
| PubChem = 10236037
| ChemSpiderID = 8411525
| smiles = O=C(O)C[C@@H](N)C[C@@H](CCC)C
| StdInChI = 1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
| StdInChIKey = JXEHXYFSIOYTAH-SFYZADRCSA-N
| bioavailability          = 
| protein_bound            = 
| metabolism               = 
| elimination_half-life    = 
| excretion                = 
| pregnancy_category       = 
| legal_status             = 
| routes_of_administration = 
}}

'''Imagabalin''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]; '''PD-332,334''') is a [[drug]] which acts as a [[ligand]] for the [[Voltage-dependent calcium channel#.CE.B12.CE.B4 Subunit|α<sub>2</sub>δ subunit]] of the [[voltage-dependent calcium channel]],<ref name="pmid21664606">{{cite journal |vauthors=Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA | title = Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology | journal = Brain Research | volume = 1401 | issue = | pages = 1–9 |date=July 2011 | pmid = 21664606 | doi = 10.1016/j.brainres.2011.05.025 | url = http://linkinghub.elsevier.com/retrieve/pii/S0006-8993(11)00910-3}}</ref> with some [[binding selectivity|selectivity]] for the [[CACNA2D1|α<sub>2</sub>δ<sub>1</sub> subunit]] over [[CACNA2D2|α<sub>2</sub>δ<sub>2</sub>]].<ref name="Ereshefsky2008">{{cite press release | title = Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models | author = Larry Ereshefsky | year = 2008 | page = 11 | url = http://www.cmellc.com/psychcongress/images/08pdf/43-5%20Ereshefsky.pdf | accessdate = 2012-04-22 | format = PDF}}</ref> Under development by [[Pfizer]] as a [[pharmaceutical drug|pharmaceutical medication]], it has demonstrated [[pre-clinical development|preclinical]] efficacy of [[anxiolytic]], [[analgesic]], [[hypnotic]], and [[anticonvulsant]]-like activity and is currently in [[phase III]] [[clinical trial]]s for the treatment of [[generalized anxiety disorder]].<ref name="Ereshefsky2008"/><ref name="ClinicalTrials2010">{{cite web | url = http://clinicaltrials.gov/ct2/show/NCT00542685 | title = A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder | accessdate = 2012-04-22}}</ref>

== See also ==

* [[Atagabalin]]
* [[PD-217,014]]
* [[Gabapentinoids]]

==References==
{{reflist|30em}}

{{Anxiolytics}}
{{Calcium channel blockers}}

[[Category:Amino acids]]
[[Category:Anxiolytics]]
[[Category:Calcium channel blockers]]
[[Category:GABA analogues]]
[[Category:Pfizer products]]
[[Category:Experimental drugs]]


{{nervous-system-drug-stub}}